A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Recruiting now · Phase 3
Conditions studied: Triple-Negative Breast Cancer (TNBC)
In brief
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
Key facts
- Study ID
- NCT06732323
- Run by
- Qilu Pharmaceutical Co., Ltd.
- People needed
- 504
- Starts
- 2025-09-04
- Expected to finish
- 2028-07-01
- Last updated by the study team
- 2025-09-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.